Drug Type Small molecule drug |
Synonyms alpha-Glutamyltryptophan, Glufanide disodium, Glutamyltryptophan + [9] |
Target- |
Mechanism Angiogenesis inhibitors, Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC16H19N3NaO5 |
InChIKeyUOKXDTZUCQYLHK-JZKFLRDJSA-N |
CAS Registry237068-57-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | Phase 3 | US | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | AU | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | BE | 31 Aug 2001 | |
Acquired Immunodeficiency Syndrome | Phase 3 | CA | 31 Aug 2001 | |
HIV Infections | Phase 3 | US | 02 Nov 1999 | |
HIV Infections | Phase 3 | AU | 02 Nov 1999 | |
HIV Infections | Phase 3 | BE | 02 Nov 1999 | |
HIV Infections | Phase 3 | CA | 02 Nov 1999 | |
Kaposi Sarcoma | Phase 3 | US | 02 Nov 1999 | |
Kaposi Sarcoma | Phase 3 | AU | 02 Nov 1999 |
Phase 2 | - | xdoygnxiia(qleejaojxf) = vopqdlbtgz bvhlmlwwep (rgyambwcxg ) | Negative | 01 Jun 2005 | |||
Placebo | xdoygnxiia(qleejaojxf) = pwzdpnircm bvhlmlwwep (rgyambwcxg ) |